SEC Form 4 · accession 0000899243-18-027509
LogicBio Therapeutics, Inc. · LOGC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Oct 23, 2018
Accepted (ET)
Oct 26, 2018 · 9:29 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001664106
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1,F2 | Oct 23, 2018 | C | 2,279,023 | — | A | 2,279,023 | I | See Footnote |
| Common stockF2 | Oct 23, 2018 | P | 700,000 | $10.00 | A | 2,979,023 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred StockF2,F1 | — | Oct 23, 2018 | C | 4,352,775 | D | — | — | Common Stock | 2,279,023 | 0 | I |
Explanation of responses
- F1The Series B Preferred Stock converted into LogicBio Therapeutics, Inc. (the "Issuer") common stock effective upon closing of the Issuer's initial public offering.
- F2These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.